[Federal Register Volume 63, Number 38 (Thursday, February 26, 1998)] [Notices] [Page 9794] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-5050] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Joint Meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- This notice announces a forthcoming meeting of public advisory committees of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committees: Joint meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee. General Function of the Committees: To provide advice and recommendations to the agency on FDA regulatory issues. Date and Time: The meeting will be held on March 11, 1998, 8 a.m. to 5 p.m. Location: Holiday Inn, Walker Room, Two Montgomery Village Ave., Gaithersburg, MD. Contact Person: Tracy Riley or Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), codes 12534 and 12536. Please call the Information Line for up-to-date information on this meeting. Agenda: The committee will discuss scientific clinical trial design for products intended for the treatment of diabetic retinopathy. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 4, 1998. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m., and between approximately 1 p.m. and 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 4, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. FDA regrets that it was unable to publish this notice 15 days prior to the joint meeting of the Dermatologic and Opthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Dermatologic and Opthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: February 20, 1998. Michael A. Friedman, Deputy Commissioner for Operations. [FR Doc. 98-5050 Filed 2-24-98; 11:42 am] BILLING CODE 4160-01-F